|
Variables
|
Histology
|
FIGO stage
|
Platinum Response
|
|---|
|
HGSC
|
CCC
|
P
|
Early (I + II)
|
Late (III + IV)
|
P
|
Sensitive
|
Resistant
|
P
|
|---|
|
CD3+ T cells (%)
|
66.88 ± 9.46
|
73.27 ± 8.07
|
0.053
|
66.56 ± 10.91
|
67.27 ± 9.21
|
0.763
|
66.99 ± 7.44
|
66.07 ± 15.14
|
0.835
|
|
CD3+CD4+T cells (%)
|
38.43 ± 9.22
|
42.18 ± 7.65
|
0.241
|
39.19 ± 8.64
|
38.47 ± 9.18
|
0.748
|
39.48 ± 7.84
|
36.67 ± 12.59
|
0.458
|
|
CD3+CD8+ T cells (%)
|
26.49 ± 8.90
|
28.82 ± 10.94
|
0.464
|
26.73 ± 11.27
|
26.87 ± 8.93
|
0.951
|
27.63 ± 8.61
|
29.39 ± 12.85
|
0.565
|
|
CD8+CD28+ T cells (%)
|
7.07 ± 2.80
|
8.51 ± 2.88
|
0.145
|
7.70 ± 2.52
|
7.23 ± 2.83
|
0.489
|
7.53 ± 2.90
|
6.67 ± 3.58
|
0.374
|
|
NK cells (CD3−CD56+) (%)
|
18.37 ± 8.95
|
14.30 ± 6.96
|
0.188
|
17.89 ± 10.08
|
18.15 ± 8.88
|
0.908
|
17.15 ± 7.34
|
21.64 ± 15.33
|
0.323
|
|
Tregs (CD4+CD25+CD127−)(%)
|
12.91 ± 3.22
|
13.79 ± 4.14
|
0.445
|
13.20 ± 3.07
|
13.02 ± 3.26
|
0.830
|
12.50 ± 2.63
|
12.47 ± 4.24
|
0.976
|
|
B cells (CD19+) (%)
|
12.40 ± 5.24
|
10.20 ± 2.15
|
0.024
|
14.99 ± 5.81
|
12.13 ± 5.05
|
0.028
|
13.61 ± 6.03
|
9.86 ± 4.07
|
0.014
|
|
CD4/CD8 ratio
|
1.67 ± 0.85
|
1.74 ± 0.91
|
0.818
|
2.40 ± 2.69
|
1.64 ± 0.82
|
0.253
|
1.88 ± 1.83
|
1.55 ± 1.00
|
0.386
|
- Abbreviations: HGSC High-Grade Serous Carcinoma, CCC Clear Cell Carcinoma, FIGO The International Federation of Gynecology and Obstetrics
